AI Article Synopsis

  • A two-day workshop on pediatric formulation development was held in June 2019, organized by M-CERSI, the FDA, and the IQ Drug Product Pediatric PWG, bringing together diverse participants from industry, regulatory bodies, and academia.
  • The workshop included sessions that covered formulation challenges, analytical strategies, clinical considerations, and regulatory insights, with a focus on improving drug product acceptability for pediatric use.
  • Key topics discussed involved dosing vehicle selection, the impact of pediatric pharmacokinetics on drug design, regional regulatory differences, and collaboration opportunities for advancing pediatric formulations.

Article Abstract

A workshop on "Pediatric Formulation Development: Challenges of Today and Strategies for Tomorrow" was organized jointly by the University of Maryland's Center of Excellence in Regulatory Science and Innovation (M-CERSI), the U.S. Food and Drug Administration (FDA) and the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Drug Product Pediatric Working Group (PWG). This multi-disciplinary, pediatric focused workshop was held over a two-day period (18-19 Jun 2019) and consisted of participants from industry, regulatory agencies, academia and other organizations from both US and Europe. The workshop consisted of sequential sessions on formulation, analytical, clinical, and regulatory and industry lessons learned and future landscape. Each session began with a series of short framing presentations, followed by facilitated breakout sessions and panel discussion. The formulation session was dedicated to three main topics pertaining to drug product acceptability, excipients in pediatrics and oral administration device considerations. The analytical session discussed key considerations for dosing vehicle selection and analytical strategies for testing of different dosage forms, specifically mini-tablets (multiparticulates). The clinical session highlighted the influence of pediatric pharmacokinetics prediction on formulation design, pediatric drug development strategies and clinical considerations to support pediatric formulation design. The regulatory and industry lessons learned and future landscape session explored the regional differences that exist in regulatory expectations, requirements for pediatric formulation development, and key patient-centric factors to consider when developing novel pediatric formulations. This session also discussed potential collaboration opportunities and tools for pediatric formulation development. This manuscript summarizes the key discussions and outcomes of all the sessions in the workshop with a broadened review and discussion of the topics that were covered.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2021.04.011DOI Listing

Publication Analysis

Top Keywords

pediatric formulation
16
formulation development
16
pediatric
9
development challenges
8
challenges today
8
today strategies
8
drug product
8
regulatory industry
8
industry lessons
8
lessons learned
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!